Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy

Journal of Medicinal Chemistry

Volumn 55, Issue 18, 2012, Pages 7957-7966

  Piotrowski, David W ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BAY 94 8862; BENZOXAZIN 2 THIONE DERIVATIVE; BENZOXAZIN 3 ONE DERIVATIVE; BENZOXAZINE DERIVATIVE; BIPHENYLAMIDE; BIPHENYLAMIDE DERIVATIVE; BR 4628; DIHYDROPYRIDINE DERIVATIVE; DROSPIRENONE; EPLERENONE; GLUCOCORTICOID RECEPTOR; LY 2623091; MEBUDIPINE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; MT 3995; PF 3882845; PROGESTERONE RECEPTOR; SM 368229; SPIRONOLACTONE; UNCLASSIFIED DRUG; XL 550;

ANTIHYPERTENSIVE ACTIVITY; BINDING SITE; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CRYSTAL STRUCTURE; DIABETIC NEPHROPATHY; DRUG ABSORPTION; DRUG DESIGN; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; GYNECOMASTIA; HEART FAILURE; HUMAN; HYDROGEN BOND; HYPERKALEMIA; HYPERTENSION; LIGAND BINDING; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; NONHUMAN; PHYSICAL CHEMISTRY; RENAL PROTECTION; REVIEW; STEREOCHEMISTRY; STEROIDOGENESIS; TESTIS ATROPHY;

ANIMALS; DIABETIC NEPHROPATHIES; DRUG DESIGN; HUMANS; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID;

EID: 84866859500     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300806c     Document Type: Review

References (82)

1. Williams, J. S.; Williams, G. H. 50th Anniversary of Aldosterone J. Clin. Endocrinol. Metab. 2003, 88, 2364-2372
2. Catena, C.; Colussi, G.; Marzano, L.; Sechi, L. A. Aldosterone and the Heart: From Basic Research to Clinical Evidence Horm. Metab. Res. 2012, 44, 181-187
3. Fourkiotis, V. G.; Hanslik, G.; Hanusch, F.; Lepenies, J.; Quinkle, M. Aldosterone and the Kidney Horm. Metab. Res. 2012, 44, 194-201
4. Epstein, M.; Calhoun, D. A. Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium-Sparing Diuretics J. Clin. Hypertens. 2011, 13, 644-648
5. Gronemeyer, H.; Gustafsson, J.-A.; Laudet, V. Principles for Modulation of the Nuclear Receptor Superfamily Nat. Rev. Drug Discovery 2004, 3, 950-964
6. Moore, J. T.; Collins, J. L.; Pearce, K. H. The Nuclear Receptor Superfamily and Drug Discovery ChemMedChem 2006, 1, 504-523
7. Leftheris, K.; Zheng, Y.; Lala, D. S. Recent Advances in Mineralocorticoid Receptor Antagonists. In Annual Reports in Medicinal Chemistry; Macor, J. E., Ed.; Academic Press: Boston, MA, 2011; Vol. 46, Chapter 6.
8. Steckelings, U. M.; Paulis, L.; Unger, T.; Bader, M. Emerging Drugs Which Target the Renin-Angiotensin-Aldosterone System Expert Opin. Emerging Drugs 2011, 16, 619-630
9. Funder, J. W. Aldosterone and Mineralocorticoid Receptors: A Personal Reflection Mol. Cell. Endocrinol. 2012, 350, 146-150
10. Odermatt, A.; Kratschmar, D. V. Tissue-Specific Modulation of Mineralocorticoid Receptor Function by 11β-Hydroxysteroid Dehydrogenases: An Overview Mol. Cell. Endocrinol. 2012, 350, 168-186
11. Huyet, J.; Pinon, G. M.; Fay, M. R.; Rafestin-Oblin, M.-E.; Fagart, J. Structural Determinants of Ligand Binding to the Mineralocorticoid Receptor Mol. Cell. Endocrinol. 2012, 350, 187-195
12. Yang, J.; Fuller, P. J. Interactions of the Mineralocorticoid Receptor-Within and Without Mol. Cell. Endocrinol. 2012, 350, 196-205
13. Young, M. J.; Rickard, A. J. Mechanisms of Mineralocorticoid Salt-Induced Hypertension and Cardiac Fibrosis Mol. Cell. Endocrinol. 2012, 350, 248-255
14. McCurley, A.; Jaffe, I. Z. Mineralocorticoid Receptors in Vascular Function and Disease Mol. Cell. Endocrinol. 2012, 350, 256-265
15. Messaoudi, S.; Azibani, F.; Delcayre, C.; Jaisser, F. Aldosterone, Mineralocorticoid Receptor, and Heart Failure Mol. Cell. Endocrinol. 2012, 350, 266-272
16. Shibata, S.; Fujita, T. Mineralocorticoid Receptors in the Pathophysiology of Chronic Kidney Diseases and the Metabolic Syndrome Mol. Cell. Endocrinol. 2012, 350, 273-280
17. Gomez-Sanchez, E. P.; Gomez-Sanchez, C. E. Central Regulation of Blood Pressure by the Mineralocorticoid Receptor Mol. Cell. Endocrinol. 2012, 350, 289-298
18. Groeneweg, F. L.; Karst, H.; de Kloet, E. R.; Joëls, M. Mineralocorticoid and Glucocorticoid Receptors at the Neuronal Membrane, Regulators of Nongenomic Corticosteroid Signaling Mol. Cell. Endocrinol. 2012, 350, 299-309
19. Kolkhof, P.; Borden, S. A. Molecular Pharmacology of the Mineralocorticoid Receptor: Prospects for Novel Therapeutics Mol. Cell. Endocrinol. 2012, 350, 310-317
20. Price, D. A.; Blagg, J.; Jones, L.; Greene, N.; Wager, T. Physicochemical Drug Properties Associated with in Vivo Toxicological Outcomes: A Review Expert Opin. Drug Metab. Toxicol. 2009, 5, 921-931
21. Meanwell, N. A. Improving Drug Candidates by Design: A Focus on Physicochemical Properties as a Means of Improving Compound Disposition and Safety Chem. Res. Toxicol. 2011, 24, 1420-1456
22. Hu, X.; Funder, J. W. The Evolution of Mineralocorticoid Receptors Mol. Endocrinol. 2006, 20, 1471-1478
23. Ménard, J. The 45-Year Story of the Development of an Anti-Aldosterone More Specific than Spironolactone Mol. Cell. Endocrinol. 2004, 217, 45-52
24. Oelkers, W. Drospirenone, a Progestogen with Antimineralocorticoid Properties: A Short Review Mol. Cell. Endocrinol. 2004, 217, 255-261
25. Corvol, P.; Michaud, A.; Menard, J.; Freifeld, M.; Mahoudeau, J. Antiandrogenic Effect of Spirolactones: Mechanism of Action Endocrinology 1975, 97, 52-58
26. Zillich, A. J.; Carter, B. L. Eplerenone-A Novel Selective Aldosterone Blocker Ann. Pharmacother. 2002, 36, 1567-1576
27. Pitt, B.; Remme, W.; Zannad, F.; Neaton, J.; Martinez, F.; Roniker, B.; Bittman, R.; Hurley, S.; Kleiman, J.; Gatlin, M. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction N. Engl. J. Med. 2003, 348, 1309-1321
28. For a recent review of multiple clinical studies with MR antagonists, see the following: Richards, A. M. Mineralocorticoid Receptor Antagonists for Heart Failure Expert Opin. Pharmacother. 2011, 12, 2801-2815
29. Khosla, N.; Kalaitzidis, R.; Bakris, G. L. Predictors of Hyperkalemia Risk following Hypertension Control with Aldosterone Blockade Am. J. Nephrol. 2009, 30, 418-424
30. Shavit, L.; Lifschitz, M. D.; Epstein, M. Aldosterone Blockade and the Mineralocorticoid Receptor in the Management of Chronic Kidney Disease: Current Concepts and Emerging Treatment Paradigms Kidney Int. 2012, 81, 955-968
31. Colby, H. D. Chemical Suppression of Steroidogenesis Environ. Health Perspect. 1981, 38, 119-127
32. Zhang, Y.-Y.; Yang, L. Interactions between Human Cytochrome P450 Enzymes and Steroids: Physiological and Pharmacological Implications Expert Opin. Drug Metab. Toxicol. 2009, 5, 621-629
33. Ye, P.; Yamashita, T.; Pollock, D. M.; Sasano, H.; Rainey, W. E. Contrasting Effects of Eplerenone and Spironolactone on Adrenal Cell Steroidogenesis Horm. Metab. Res. 2009, 41, 35-39
34. Dore, J.-C.; Gilbert, J.; Ojasoo, T.; Raynaudt, J.-P. Correspondence Analysis Applied to Steroid Receptor Binding J. Med. Chem. 1986, 29, 54-60
35. Fagart, J.; Wurtz, J. M.; Souque, A.; Hellal-Levy, C.; Moras, D.; Rafestin-Oblin, M. E. Antagonism in the Human Mineralocorticoid Receptor EMBO J. 1998, 17, 3317-3325
36. Park, S.-J.; Kufareva, I.; Abagyan, R. Improved Docking, Screening and Selectivity Prediction for Small Molecule Nuclear Receptor Modulators Using Conformational Ensembles J. Comput.-Aided Mol. Des. 2010, 24, 459-471
37. Babine, R. E. Molecular Recognition of Nuclear Receptor-Ligand Complexes. In Protein Crystallography in Drug Discovery; Babine, R. E.; Abdel-Meguid, S. S., Eds.; Wiley-VCH: Weinheim, Germany, 2004; Chapter 1.
38. Huang, P.; Chandra, V.; Rastinejad, F. Structural Overview of the Nuclear Receptor Superfamily: Insights into Physiology and Therapeutics Annu. Rev. Physiol. 2010, 72, 247-272
39. Sartorato, P.; Cluzeaud, F.; Fagart, J.; Viengchareun, S.; Lombès, M.; Zennaro, M.-C. New Naturally Occurring Missense Mutations of the Human Mineralocorticoid Receptor Disclose Important Residues Involved in Dynamic Interactions with Deoxyribonucleic Acid, Intracellular Trafficking, and Ligand Binding Mol. Endocrinol. 2004, 18, 2151-2165
40. Pinon, G. M.; Fagart, J.; Souque, A.; Auzoub, G.; Vandewalle, A.; Rafestin-Oblin, M.-E. Identification of Steroid Ligands Able To Inactivate the Mineralocorticoid Receptor Harboring the S810L Mutation Responsible for a Severe Form of Hypertension Mol. Cell. Endocrinol. 2004, 217, 181-188
41. Meyers, M. J.; Hu, X. Non-Steroidal Mineralocorticoid Receptor Antagonists Expert Opin. Ther. Pat. 2007, 17, 17-23
42. Mestres, J.; Gregori-Puigjané, E.; Valverde, S.; Sole, R. S. The Topology of Drug-Target Interaction Networks: Implicit Dependence on Drug Properties and Target Families Mol. BioSyst. 2009, 5, 1051-1057
43. Miller, J. L. Recent Developments in Focused Library Design: Targeting Gene-Families Curr. Top. Med. Chem. 2006, 6, 19-29
44. Wyatt, P. G.; Gilbert, I. H.; Read, K. D.; Fairlamb, A. H. Target Validation: Linking Target and Chemical Properties to Desired Product Profile Curr. Top. Med. Chem. 2011, 11, 1275-1283
45. Paolini, G. V.; Shapland, R. H. B.; van Hoorn, W. P.; Mason, J. S.; Hopkins, A. L. Global Mapping of Pharmacological Space Nat. Biotechnol. 2006, 24, 805-815
46. Vieth, M.; Sutherland, J. J. Dependence of Molecular Properties on Proteomic Family for Marketed Oral Drugs J. Med. Chem. 2006, 49, 3451-3453
47. Morphy, R. The Influence of Target Family and Functional Activity on the Physicochemical Properties of Pre-Clinical Compounds J. Med. Chem. 2006, 49, 2969-2978
48. Pipeline on Eli Lilly Web site at http://www.lilly.com.
49. Information obtained from http://clinicaltrials.gov.
50. Fagart, J.; Hillisch, A.; Huyet, J.; Barfacker, L.; Fay, M.; Pleiss, U.; Pook, E.; Schafer, S.; Rafestin-Oblin, M.-E.; Kolkhof, P. A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule J. Biol. Chem. 2010, 285, 29932-29940
51. Kuhl, A.; Kolkhof, P.; Heckroth, H.; Schlemmer, K.-H.; Flamme, I.; Figueroa Perez, S.; Gielen-Haertwig, H.; Grosser, R.; Erguden, J.-K.; Lang, D. 4-Chromenonyl-1,4-dihydropyridines and Their Use. PCT Int. Appl. WO2007025604, 2007.
52. Barfacker, L.; Kolkhof, P.; Schlemmer, K.-H.; Grosser, R.; Nitsche, A.; Klein, M.; Munter, K.; Albrecht-Kupper, B.; Hartmann, E. Substituted 4-Aryl-1,4-dihydro-1,6-naphthyridinamides and Use Thereof. PCT Int. Appl. WO2008104306, 2008.
53. Information disclosed on Bayer Trial Finder Web site at http://www.bayerhealthcare.com.
54. Dietz, J. D.; Du, S.; Bolten, C. W.; Payne, M. A.; Xia, C.; Blinn, J. R.; Funder, J. W.; Hu, X. A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity Hypertension 2008, 51, 742-748
55. Arhancet, G. B.; Woodard, S. S.; Dietz, J. D.; Garland, D. J.; Wagner, G. M.; Iyanar, K.; Collins, J. T.; Blinn, J. R.; Numann, R. E.; Hu, X.; Huang, H.-C. Stereochemical Requirements for the Mineralocorticoid Receptor Antagonist Activity of Dihydropyridines J. Med. Chem. 2010, 53, 4300-4304
56. Arhancet, G. B.; Woodard, S. S.; Iyanar, K.; Case, B. L.; Woerndle, R.; Dietz, J. D.; Garland, D. J.; Collins, J. T.; Payne, M. A.; Blinn, J. R.; Pomposiello, S. I.; Hu, X.; Heron, M. I.; Huang, H. C.; Lee, L. F. Discovery of Novel Cyanodihydropyridines as Potent Mineralocorticoid Receptor Antagonists J. Med. Chem. 2010, 53, 5970-5978
57. Meyers, M. J.; Arhancet, G. B.; Hockerman, S. L.; Chen, X.; Long, S. A.; Mahoney, M. W.; Rico, J. R.; Garland, D. J.; Blinn, J. R.; Collins, J. T.; Yang, S.; Huang, H.-C.; McGee, K. F.; Wendling, J. M.; Dietz, J. D.; Payne, M. A.; Homer, B. L.; Heron, M. I.; Reitz, D. B.; Hu, X. Discovery of (3 S,3a R)-2-(3-Chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2 H -benzo[ g ]indazole-7-carboxylic Acid (PF-3882845), an Orally Efficacious Mineralocorticoid Receptor (MR) Antagonist for Hypertension and Nephropathy J. Med. Chem. 2010, 53, 5979-6002
58. Eudy, R. J.; Sahasrabudhe, V.; Sweeney, K.; Tugnait, M.; King-Ahmad, A.; Near, K.; Loria, P.; Banker, M. E.; Piotrowski, D. W.; Boustany-Kari, C. M. The Use of Plasma Aldosterone and Urinary Sodium to Potassium Ratio as Translatable Quantitative Biomarkers of Mineralocorticoid Receptor Antagonism J. Transl. Med. 2011, 9, 180
59. Boos, C.; Bowles, D. M.; Cai, C.; Casimiro-Garcia, A.; Chen, X.; Hulford, C. A.; Jennings, S. M.; Kiser, E. J.; Piotrowski, D. W.; Sammons, M.; Wade, R. A. Synthesis and Cross Coupling of a Highly Substituted 2-Pyridylboronate: Application to the Large Scale Synthesis of a Mineralocorticoid Antagonist Tetrahedron Lett. 2011, 52, 7025-7029
60. Huang, Z.; Wang, J. Fused Ring Compound for Use as Mineralocorticoid Receptor Antagonist. PCT Int. Appl. WO2012022121, 2012.
61. Zhang, Y.; Chen, J. Dihydropyrazole Compounds. PCT Int. Appl. WO2012022120, 2012.
62. Casimiro-Garcia, A.; Futatsugi, K.; Piotrowski, D. W. Morpholine Compounds as Mineralocorticoid Receptor Antagonists. PCT Int. Appl. WO2011141848, 2011.
63. Pipeline information obtained from the Mitsubishi Tanabe Web site http://www.mt-pharma.co.jp/e/
64. + Excretion Activity J. Pharmacol. Sci. 2011, 115, 346-353
65. Nariai, T.; Fujita, K.; Mori, M.; Katayama, S.; Hori, S.; Matsui, K. Antihypertensive and Cardiorenal Protective Effects of SM-368229, a Novel Mineralocorticoid Receptor Antagonist, in Aldosterone/Salt-Treated Rats Pharmacology 2012, 89, 44-52
66. Nariai, T.; Fujita, K.; Mori, M.; Katayama, S.; Hori, S.; Matsui, K. SM-368229, a Novel Promising Mineralocorticoid Receptor Antagonist, Shows Anti-Hypertensive Efficacy with Minimal Effect on Serum Potassium Level in Rats J. Cardiovasc. Pharmacol. 2012, 59, 458-464
67. Katayama, S.; Hori, S.; Hasegawa, F.; Suzuki, K. Biaryl Amide Derivative or Pharmaceutically Acceptable Salt Thereof. PCT Int. Appl. WO2012008435, 2012.
68. Aoki, K.; Tsuruoka, H.; Hayashi, N.; Yoshida, J.; Asoh, Y. Atropisomer of Pyrrole Derivative. PCT Int. Appl. WO2008126831, 2008.
69. Pipeline information obtained from the Exelixis Web site http://www.exelixis.com
70. Hasui, T.; Matsunaga, N.; Ora, T.; Ohyabu, N.; Nishigaki, N.; Imura, Y.; Igata, Y.; Matsui, H.; Motoyaji, T.; Tanaka, T.; Habuka, N.; Sogabe, S.; Ono, M.; Siedem, C. S.; Tang, T. P.; Gauthier, C.; De Meese, L. A.; Boyd, S. A.; Fukumoto, S. Identification of Benzoxazin-3-one Derivatives as Novel, Potent, and Selective Nonsteroidal Mineralocorticoid Receptor Antagonists J. Med. Chem. 2011, 54, 8616-8631
71. Michellys, P.-Y.; Petrassi, H. M.; Richmond, W.; Pei, W. Compounds and Compositions as Modulators of Steroid Hormone Nuclear Receptors. PCT Intl. Appl. WO2006015259, 2006.
72. Boyer, S. J.; Guo, X.; Wu, D.; Wu, F. Pyridyl Ureas as Mineralocorticoid Receptor Antagonists. PCT Intl. Appl. WO2012064631, 2012.
73. Fleming, F. F.; Yao, L.; Ravikumar, P. C.; Funk, L.; Shook, B. C. Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore J. Med. Chem. 2010, 53, 7902-7917
74. Fagart, J.; Huyet, J.; Pinon, G. M.; Rochel, M.; Mayer, C.; Rafestin-Oblin, M. E. Crystal Structure of a Mutant Mineralocorticoid Receptor Responsible for Hypertension Nat. Struct. Mol. Biol. 2005, 12, 554-555. Also see references cited in ref 7c
75. Bledsoe, R. K.; Madauss, K. P.; Holt, J. A.; Apolito, C. J.; Lambert, M. H.; Pearce, K. H.; Stanley, T. B.; Stewart, E. L.; Trump, R. P.; Willson, T. M.; Williams, S. P. A Ligand-Mediated Hydrogen Bond Network Required for the Activation of the Mineralocorticoid Receptor J. Biol. Chem. 2005, 280, 31283-31293
76. McEwan, I. J.; Nardulli, A. M. Nuclear Hormone Receptor Architecture-Form and Dynamics: The 2009 FASEB Summer Conference on Dynamic Structure of the Nuclear Hormone Receptors Nucl. Recept. Signaling Atlas 2007, 5, e012
77. Chandra, V.; Huang, P.; Hamuro, Y.; Raghuram, S.; Wang, Y.; Burris, T. P.; Rastinejad, F. Structure of the Intact PPAR-γ-RXR-Nuclear Receptor Complex on DNA Nature 2008, 456, 350-356
78. Pippal, J. B.; Yao, Y.; Rogerson, F. M.; Fuller, P. Structural and Functional Characterization of the Interdomain Interaction in the Mineralocorticoid Receptor J. Mol. Endocrinol. 2009, 23, 1360-1370
79. Zhou, X. E.; Suino-Powell, K.; Ludidi, P. L.; McDonnell, D. P.; Xu, H. E. Expression, Purification and Primary Crystallographic Study of Human Androgen Receptor in Complex with DNA and Coactivator Motifs Protein Expression Purif. 2010, 71, 21-27
80. Zhang, Z.; Olland, A. M.; Zhu, Y.; Cohen, J.; Berrodin, T.; Chippari, S.; Appavu, C.; Li, S.; Wilhem, J.; Chopra, R.; Fensome, A.; Zhang, P.; Wrobel, J.; Unwalla, R. J.; Lyttle, C. R.; Winneker, R. C. Molecular and Pharmacological Properties of a Potent and Selective Novel Nonsteroidal Progesterone Receptor Agonist Tanaproget J. Biol. Chem. 2005, 280, 28468-28475
81. Yang, J.; Young, M. J. The Mineralocorticoid Receptor and Its Coregulators J. Mol. Endocrinol. 2009, 43, 53-64
82. Moore, T. W.; Mayne, C. G.; Katzenellenbogen, J. A. Minireview: Not Picking Pockets: Nuclear Receptor Alternate-Site Modulators (NRAMs) Mol. Endocrinol. 2010, 24, 683-695